<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713776</url>
  </required_header>
  <id_info>
    <org_study_id>2014_880</org_study_id>
    <nct_id>NCT02713776</nct_id>
  </id_info>
  <brief_title>Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment</brief_title>
  <acronym>SOMILEO</acronym>
  <official_title>Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment : Phase II Multicentric Randomized Double Bland Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <brief_summary>
    <textblock>
      During rectal or complex digestive surgery with multiple digestive resections and&#xD;
      anastomosis, the creation of enterostomy is a common procedure. In France, it is estimated&#xD;
      that 20000 patients have an ileostomy and 16000 new digestive stomas are formed each year&#xD;
      with approximately 30% of enterostomy. Enterostomy might sometimes give high-output not&#xD;
      controlled with usual medical treatment (e.g loperamide ± codeine) and exposes the patients&#xD;
      to important hydro-electrolytic loss leading to a risk for dehydration, electrolyte&#xD;
      abnormalities and acute renal failure. This risk implies parenteral correction which may&#xD;
      extend hospital stay and delay home return.&#xD;
&#xD;
      Somatostatin analogues (octreotide, lanreotide and pasireotide) could reduce digestive&#xD;
      secretions and decrease digestive peristalsis. Nevertheless, somatostatin analogues are not&#xD;
      routinely used for the treatment of patients with high-output enterostomy and their efficacy&#xD;
      in the indication (off-label) was only tested in small case series. Pasireotide (SOM230,&#xD;
      SIGNIFOR®) is currently indicated for the treatment of patients with Cushing's disease for&#xD;
      whom surgery is not an option or for whom surgery has failed.&#xD;
&#xD;
      As the efficacity of pasireotide in patients with high-output enterostomy refractory to usual&#xD;
      medical treatment associated with an oral fluid restriction has never been demonstrated&#xD;
      before, there is a need to perform a pilot, double-blind, randomized, placebo-controlled&#xD;
      trial evaluating its impact on reduction of the effluent volume.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 13, 2016</start_date>
  <completion_date type="Anticipated">January 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 24, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the efficacy of pasireotide versus placebo in reduction of high-output</measure>
    <time_frame>Evaluated 72 hours after first injection of treatment</time_frame>
    <description>Decrease of enterostomy output (ml/24H)within the 72 hours after first injection of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the success rate of pasireotide and placebo</measure>
    <time_frame>1 week after first injection of treatment</time_frame>
    <description>Number of normal renal function patients in both arms with an enterostomy output than 800 millimeters (mL) /24h within a week after first injection of treatment allowing discontinuation of intravenous perfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the decrease in the length of hospitalization with pasireotide versus placebo</measure>
    <time_frame>1 month after the end of treatment</time_frame>
    <description>Duration of hospitalization in days in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the incidence of premature closure of stoma due to high-output with pasireotide versus placebo</measure>
    <time_frame>2 months after enterostomy creation</time_frame>
    <description>Rate of premature closure of stoma due to high-output (before 2 months after creation) in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the economic impact of pasireotide in this indication</measure>
    <time_frame>2 months from the inclusion of the patient in the study</time_frame>
    <description>Costs of taking care of patients from French Public Health Insurance perspective in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment - Emergent Adverse Events</measure>
    <time_frame>during treatment (4 days), one week, two weeks, three weeks and one month after treatment</time_frame>
    <description>Nature, number and grade of adverse events observed throughout the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Enterostomy</condition>
  <arm_group>
    <arm_group_label>Pasireotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pasireotide</intervention_name>
    <description>Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.</description>
    <arm_group_label>Pasireotide</arm_group_label>
    <other_name>Pasireotide 0.9 mg (SIGNIFOR®) and Pasireotide 60mg Long Acting Release (LAR)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo of pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide LAR (Long Acting Release) 60mg on Day 4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and Female patients ≥ 18 years old ;&#xD;
&#xD;
          -  Patients who underwent an intestinal surgery with enterostomy repair in the three&#xD;
             weeks preceding the inclusion ;&#xD;
&#xD;
          -  Patients with high-output ileostomy or jejunostomy &gt; 1000 ml/24h ;&#xD;
&#xD;
          -  Patients with failure of treatment combining oral fluid restriction and loperamide (up&#xD;
             to 8 capsules/24h) +/- codeine syrup (10 mg x 3/24h) during 5 days ;&#xD;
&#xD;
          -  Patients who gave its written informed consent to participate to the study ;&#xD;
&#xD;
          -  Patients affiliated to a social insurance regime.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male and Female patients &lt; 18 years old ;&#xD;
&#xD;
          -  Patients who did not give its written informed consent to participate to the study ;&#xD;
&#xD;
          -  Patients who received somatostatin analogues during the month before inclusion ;&#xD;
&#xD;
          -  Patients with symptomatic cholelithiasis or acute or chronic pancreatitis ;&#xD;
&#xD;
          -  Patients with uncontrolled diabetes (with HbA1c (glycated hemoglobin) &gt; 8%) ;&#xD;
&#xD;
          -  Patients who are hypothyroid and not on adequate replacement therapy ;&#xD;
&#xD;
          -  Patients who have congestive heart failure (NYHA (New York Heart Association) Class&#xD;
             III or IV), unstable angina, sustained ventricular tachycardia, ventricular&#xD;
             fibrillation, advanced heart block or a history of clinically significant bradycardia&#xD;
             or acute myocardial infarction within the 6 months preceding randomization ;&#xD;
&#xD;
          -  Patients with history of syncope or family history of idiopathic sudden death ;&#xD;
&#xD;
          -  Patients with screening or baseline (predose) : QT interval corrected for heart rate&#xD;
             using Fridericia's correction (QTcF) QTcF &gt; 450 msec (male), QTcF &gt; 460 msec (female)&#xD;
             (QT interval corrected for heart rate using Fridericia's correction) ;&#xD;
&#xD;
          -  Patients with not corrected hypokalaemia and/or hypomagnesaemia ;&#xD;
&#xD;
          -  Patients with liver disease such as cirrhosis, chronic active hepatitis, or chronic&#xD;
             persistent hepatitis, or patients with alanine transaminase/aspartate transaminase&#xD;
             (ALT/AST) &gt; 2 x Upper Limit of Normal (ULN), serum bilirubin &gt; 2 x ULN ;&#xD;
&#xD;
          -  Patients with Child-Pugh C cirrhosis ;&#xD;
&#xD;
          -  Female patients who are pregnant or lactating, or are of childbearing potential and&#xD;
             not practicing a medically acceptable method of birth control ;&#xD;
&#xD;
          -  Patients with active malignant disease within the last five years (with the exception&#xD;
             of basal cell carcinoma or carcinoma in situ of the cervix) ;&#xD;
&#xD;
          -  Patients with abnormal coagulation (PT and/or APTT elevated by 30% above normal&#xD;
             limits) or patients receiving anticoagulants that affect PT (prothrombin time) or&#xD;
             activated partial thromboplastin time (APTT) ;&#xD;
&#xD;
          -  Patients with known hypersensitivity to somatostatin analogues or any other component&#xD;
             of the pasireotide LAR ;&#xD;
&#xD;
          -  Patients under guardianship ;&#xD;
&#xD;
          -  Patients nonaffiliated to a social insurance regime.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eddy COTTE, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon - Centre Hospitalier Lyon Sud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chu Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Albert Michallon</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude HURIEZ - CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59 067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Marseille - Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13 915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Regional Du Cancer Val D'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Caremeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bordeaux Chu - Hopital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rouen Ch. Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulouse - Chu Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High-Output Enterostomy</keyword>
  <keyword>Pasireotide</keyword>
  <keyword>Somatostatin Analogues</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pasireotide</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

